Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Schouten PC"" wg kryterium: Autor


Wyświetlanie 1-8 z 8
Tytuł:
Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
Autorzy:
Wang Y; Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Dackus GMHE; Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Rosenberg EH; Division of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Cornelissen S; Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.
de Boo LW; Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Broeks A; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Brugman W; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Chan TWS; Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
van Diest PJ; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Hauptmann M; Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.
Ter Hoeve ND; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Isaeva OI; Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
de Jong VMT; Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Jóźwiak K; Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.
Kluin RJC; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Kok M; Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Koop E; Department of Pathology, Gelre Ziekenhuizen, Apeldoorn, The Netherlands.
Nederlof PM; Division of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Opdam M; Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Schouten PC; Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Siesling S; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.; Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands.
van Steenis C; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Voogd AC; Department of Epidemiology, Maastricht University, Maastricht, The Netherlands.
Vreuls W; Department of Pathology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands.
Salgado RF; Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Center, Melbourne, Australia.
Linn SC; Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Schmidt MK; Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. .; Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. .
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2024 Jan 09; Vol. 22 (1), pp. 9. Date of Electronic Publication: 2024 Jan 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Neoplasms, Second Primary*
Humans ; Female ; Adult ; Adjuvants, Immunologic ; Ethnicity ; Biomarkers ; BRCA1 Protein/genetics
Czasopismo naukowe
Tytuł:
Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.
Autorzy:
van Wagensveld L; Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), 3511 DT Utrecht, The Netherlands.; Department of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; GROW, School for Oncology and Reproduction, 6229 HX Maastricht, The Netherlands.
van Baal JOAM; Department of Gynecology, Center for Gynecologic Oncology Amsterdam (CGOA), 1066 CX Amsterdam, The Netherlands.
Timmermans M; Department of Obstetrics and Gynecology, Leiden University Medical Centre, 2333 ZA Leiden, The Netherlands.
Gaillard D; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Borghuis L; Department of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Coffelt SB; Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Institute of Cancer Sciences, University of Glasgow, Glasgow G12 8QQ, UK.; Cancer Research UK, Beatson Institute, Glasgow G61 1BD, UK.
Rosenberg EH; Department of Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Lok CAR; Department of Gynecology, Center for Gynecologic Oncology Amsterdam (CGOA), 1066 CX Amsterdam, The Netherlands.
Nijman HW; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
Kooreman LFS; GROW, School for Oncology and Reproduction, 6229 HX Maastricht, The Netherlands.; Department of Pathology, Maastricht University Medical Centre, 6229 HX Maastricht, The Netherlands.
Sanders J; Department of Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
de Bruijn M; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
Wessels LFA; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
van der Wiel R; Department of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Rausch C; Department of Pathology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands.; BioLizard nv, 9000 Ghent, Belgium.
Broeks A; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Kruitwagen RFPM; GROW, School for Oncology and Reproduction, 6229 HX Maastricht, The Netherlands.; Department of Obstetrics and Gynecology, Maastricht University Medical Centre, 6229 HX Maastricht, The Netherlands.
van der Aa MA; Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), 3511 DT Utrecht, The Netherlands.
Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Schouten PC; Department of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Van de Vijver KK; Department of Gynecology, Center for Gynecologic Oncology Amsterdam (CGOA), 1066 CX Amsterdam, The Netherlands.; Department of Pathology & Cancer Research Institute Ghent (CRIG), Ghent University Hospital, 9000 Ghent, Belgium.
Horlings HM; Department of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 Dec 02; Vol. 14 (23). Date of Electronic Publication: 2022 Dec 02.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Autorzy:
Schouten PC; Department of Molecular Pathology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
Dackus GM; Department of Molecular Pathology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.; Department of Pathology, Utrecht University Medical Center, Heidelberglaan 100, 3584CX, Utrecht, The Netherlands.
Marchetti S; Division of Medical Oncology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.; Department of Clinical Pharmacology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
van Tinteren H; Department of Biometrics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
Sonke GS; Division of Medical Oncology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
Schellens JH; Department of Molecular Pathology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.; Division of Medical Oncology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.; Department of Clinical Pharmacology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.; Faculty of Science, Utrecht Institute of Pharmaceutical Sciences (UIPS), Universiteitsweg 99, 3584CG, Utrecht, The Netherlands.
Linn SC; Department of Molecular Pathology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. .; Department of Pathology, Utrecht University Medical Center, Heidelberglaan 100, 3584CX, Utrecht, The Netherlands. .; Division of Medical Oncology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. .
Pokaż więcej
Źródło:
Trials [Trials] 2016 Jun 21; Vol. 17 (1), pp. 293. Date of Electronic Publication: 2016 Jun 21.
Typ publikacji:
Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Biomarkers, Tumor*/analysis
Biomarkers, Tumor*/genetics
Mutation*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
BRCA1 Protein/*genetics
BRCA2 Protein/*genetics
Breast Neoplasms/*drug therapy
Capecitabine/*administration & dosage
Carboplatin/*administration & dosage
Phthalazines/*administration & dosage
Piperazines/*administration & dosage
Receptor, ErbB-2/*analysis
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Breast Neoplasms/enzymology ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Capecitabine/adverse effects ; Carboplatin/adverse effects ; Carboplatin/pharmacokinetics ; Clinical Protocols ; Compassionate Use Trials ; Disease Progression ; Disease-Free Survival ; Drug Dosage Calculations ; Female ; Genetic Predisposition to Disease ; Humans ; Netherlands ; Phenotype ; Phthalazines/adverse effects ; Phthalazines/pharmacokinetics ; Piperazines/adverse effects ; Piperazines/pharmacokinetics ; Research Design ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.
Autorzy:
Michaut M; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Chin SF; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
Majewski I; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Severson TM; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Bismeijer T; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
de Koning L; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France.
Peeters JK; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands.
Schouten PC; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Rueda OM; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
Bosma AJ; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Tarrant F; Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.; OncoMark Limited, NovaUCD, Belfield Innovation Park, Dublin 4, Ireland.
Fan Y; Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.
He B; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France.
Xue Z; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Mittempergher L; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Kluin RJ; Genomic Core Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Heijmans J; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands.
Snel M; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands.
Pereira B; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
Schlicker A; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Provenzano E; Cambridge Experimental Cancer Medicine Centre (ECMR) and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.; Cambridge Breast Unit and Cambridge University Hospitals, NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK.
Ali HR; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.; Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QP, UK.
Gaber A; Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 85 Lund, Sweden.
O'Hurley G; OncoMark Limited, NovaUCD, Belfield Innovation Park, Dublin 4, Ireland.
Lehn S; Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 85 Lund, Sweden.
Muris JJ; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Wesseling J; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Kay E; Department of Pathology, RCSI ERC, Beaumont Hospital, Dublin 9, Ireland.
Sammut SJ; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
Bardwell HA; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
Barbet AS; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France.
Bard F; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France.
Lecerf C; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France.
O'Connor DP; Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.
Vis DJ; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Benes CH; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
McDermott U; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Garnett MJ; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Simon IM; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands.
Jirström K; Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 85 Lund, Sweden.
Dubois T; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France.
Linn SC; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Division of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Gallagher WM; Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.; OncoMark Limited, NovaUCD, Belfield Innovation Park, Dublin 4, Ireland.
Wessels LF; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Department of EEMCS, Delft University of Technology, Delft, The Netherlands.
Caldas C; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.; Cambridge Experimental Cancer Medicine Centre (ECMR) and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.; Cambridge Breast Unit and Cambridge University Hospitals, NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK.; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0QQ, UK.
Bernards R; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands.; Cancer Genomics Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2016 Jan 05; Vol. 6, pp. 18517. Date of Electronic Publication: 2016 Jan 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Genomics*/methods
Proteome*
Transcriptome*
Breast Neoplasms/*genetics
Breast Neoplasms/*metabolism
Carcinoma, Lobular/*genetics
Carcinoma, Lobular/*metabolism
Biomarkers, Tumor ; Breast Neoplasms/diagnosis ; Breast Neoplasms/mortality ; Carcinoma, Lobular/diagnosis ; Cluster Analysis ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; Epithelial-Mesenchymal Transition/genetics ; Female ; Gene Expression Profiling ; Humans ; Immunohistochemistry ; Mutation Rate ; Polymorphism, Single Nucleotide ; Prognosis ; Proteomics ; Reproducibility of Results ; Transcription Factors/genetics ; Transcription Factors/metabolism
Czasopismo naukowe
Tytuł:
REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
Autorzy:
Xu G; Division of Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Chapman JR; The Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, United Kingdom.
Brandsma I; Department of Genetics, Erasmus, University Medical Center, Rotterdam, The Netherlands.
Yuan J; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Mistrik M; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
Bouwman P; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Bartkova J; Danish Cancer Society Research Center, Copenhagen, Denmark.
Gogola E; Division of Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Warmerdam D; Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Barazas M; Division of Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Jaspers JE; Division of Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Watanabe K; Danish Cancer Society Research Center, Copenhagen, Denmark.
Pieterse M; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Kersbergen A; Division of Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Sol W; Division of Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Celie PHN; Protein Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Schouten PC; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
van den Broek B; Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Salman A; The Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, United Kingdom.
Nieuwland M; Deep Sequencing Core Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
de Rink I; Deep Sequencing Core Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
de Ronde J; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Jalink K; Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Boulton SJ; DNA Damage Response Laboratory, London Research Institute, Cancer Research UK, Clare Hall, South Mimms EN6 3LD, UK.
Chen J; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
van Gent DC; Department of Genetics, Erasmus, University Medical Center, Rotterdam, The Netherlands.
Bartek J; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.; Danish Cancer Society Research Center, Copenhagen, Denmark.
Jonkers J; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Borst P; Division of Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Rottenberg S; Division of Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Laengassstrasse 122, 3012 Bern, Switzerland.
Pokaż więcej
Źródło:
Nature [Nature] 2015 May 28; Vol. 521 (7553), pp. 541-544. Date of Electronic Publication: 2015 Mar 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
DNA Breaks, Double-Stranded*
Poly(ADP-ribose) Polymerase Inhibitors*
Recombinational DNA Repair*
Mad2 Proteins/*metabolism
Adaptor Proteins, Signal Transducing ; Animals ; Ataxia Telangiectasia Mutated Proteins/antagonists & inhibitors ; Ataxia Telangiectasia Mutated Proteins/metabolism ; BRCA1 Protein/deficiency ; BRCA1 Protein/genetics ; BRCA1 Protein/metabolism ; Cell Cycle Proteins ; Cell Line ; Chromatin/metabolism ; Chromosomal Proteins, Non-Histone/metabolism ; DNA-Binding Proteins/metabolism ; Drug Resistance, Neoplasm/genetics ; Histones/metabolism ; Humans ; Immunoglobulin Class Switching/genetics ; Intracellular Signaling Peptides and Proteins/metabolism ; Mad2 Proteins/deficiency ; Mad2 Proteins/genetics ; Mice ; Nuclear Proteins/metabolism ; Trans-Activators/metabolism ; Tumor Suppressor p53-Binding Protein 1 ; Ubiquitin-Protein Ligases/metabolism
Czasopismo naukowe
Tytuł:
Lack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastases.
Autorzy:
Vollebergh MA; Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Division of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Klijn C; Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Schouten PC; Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Wesseling J; Department of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Israeli D; Department of Pathology, Vrije Universiteit University Medical Center, Amsterdam, the Netherlands.
Ylstra B; Department of Pathology, Vrije Universiteit University Medical Center, Amsterdam, the Netherlands.
Wessels LF; Department of Bioinformatics and Statistics, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, the Netherlands.
Jonkers J; Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Linn SC; Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Division of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2014 Aug 01; Vol. 9 (8), pp. e103177. Date of Electronic Publication: 2014 Aug 01 (Print Publication: 2014).
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Genetic Heterogeneity*
Breast Neoplasms/*genetics
Breast Neoplasms/*pathology
Lymph Nodes/*pathology
Breast Neoplasms/metabolism ; Cluster Analysis ; Comparative Genomic Hybridization ; DNA Copy Number Variations ; Female ; Genomic Instability ; Genomics ; Humans ; Lymphatic Metastasis ; Prognosis ; Triple Negative Breast Neoplasms
Czasopismo naukowe
Tytuł:
Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation.
Autorzy:
van Miltenburg MH; 1] Division of Toxicology, Leiden/Amsterdam Center for Drug Research, Leiden University, Einsteinweg 55, P.O. Box 9502, 2300 RA Leiden, The Netherlands [2] Division of Molecular Pathology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
van Nimwegen MJ; Division of Toxicology, Leiden/Amsterdam Center for Drug Research, Leiden University, Einsteinweg 55, P.O. Box 9502, 2300 RA Leiden, The Netherlands.
Tijdens I; Division of Toxicology, Leiden/Amsterdam Center for Drug Research, Leiden University, Einsteinweg 55, P.O. Box 9502, 2300 RA Leiden, The Netherlands.
Lalai R; Division of Toxicology, Leiden/Amsterdam Center for Drug Research, Leiden University, Einsteinweg 55, P.O. Box 9502, 2300 RA Leiden, The Netherlands.
Kuiper R; Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Karolinska vägen, 171 76 Solna, Sweden.
Klarenbeek S; Division of Molecular Pathology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Schouten PC; Division of Molecular Pathology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
de Vries A; Laboratory of Toxicology, Pathology and Genetics, National Institute for Public Health and the Environment, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands.
Jonkers J; Division of Molecular Pathology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
van de Water B; Division of Toxicology, Leiden/Amsterdam Center for Drug Research, Leiden University, Einsteinweg 55, P.O. Box 9502, 2300 RA Leiden, The Netherlands.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 May 27; Vol. 110 (11), pp. 2747-55. Date of Electronic Publication: 2014 May 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma/*enzymology
Carcinosarcoma/*enzymology
Focal Adhesion Kinase 1/*genetics
Mammary Neoplasms, Experimental/*enzymology
Tumor Suppressor Protein p53/*metabolism
Animals ; Carcinogenesis/metabolism ; Carcinoma/genetics ; Carcinoma/pathology ; Carcinosarcoma/genetics ; Carcinosarcoma/pathology ; Cell Proliferation ; Epithelial Cells/enzymology ; Female ; Focal Adhesion Kinase 1/deficiency ; Humans ; Incidence ; Mammary Glands, Animal/enzymology ; Mammary Glands, Animal/pathology ; Mammary Neoplasms, Experimental/genetics ; Mammary Neoplasms, Experimental/pathology ; Mice ; Mice, Inbred C57BL ; Mutation, Missense ; Tumor Burden ; Tumor Suppressor Protein p53/genetics
Czasopismo naukowe
Tytuł:
The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry.
Autorzy:
Zeestraten EC; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Benard A
Reimers MS
Schouten PC
Liefers GJ
van de Velde CJ
Kuppen PJ
Pokaż więcej
Źródło:
Biomarkers in cancer [Biomark Cancer] 2013 Jul 04; Vol. 5, pp. 13-29. Date of Electronic Publication: 2013 Jul 04.
Typ publikacji:
Journal Article; Review
Czasopismo naukowe
    Wyświetlanie 1-8 z 8

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies